|Table of Contents|

Retrospective analysis of hematologic toxicity among ovarian cancer patients with germline BRCA1/2 mutation status during initial platinum-based chemotherapy

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 02
Page:
311-315
Research Field:
Publishing date:

Info

Title:
Retrospective analysis of hematologic toxicity among ovarian cancer patients with germline BRCA1/2 mutation status during initial platinum-based chemotherapy
Author(s):
HAN Lu1; WANG Qi1; JING Wei2; BIN Yadi1; ZHOU Xue1; LI Qiling1
1.Department of Obstetrics and Gynecology,the First Affiliated Hospital of Xi'an Jiaotong University,Shaanxi Xi'an 710061,China;2.Department of Gynecologic Oncology,Shaanxi Provincial Cancer Hospital,Shaanxi Xi'an 710061,China.
Keywords:
ovarian cancer; BRCA1/2 mutation; hematological toxicity
PACS:
R737.31
DOI:
10.3969/j.issn.1672-4992.2023.02.021
Abstract:
Objective:To explore the effect of germline BRCA1/2 mutation (gBRCA1/2m) status on hematologic toxicity among ovarian cancer patients undergoing initial platinum-based chemotherapy.Methods:The clinical data of patients with primary ovarian,peritoneal and/or fallopian tube cancer,including FIGO stage,pathological type,chemotherapy regimen and blood system index after chemotherapy were reviewed and analyzed from January 2019 to December 2021 in the First Affiliated Hospital of Xi'an Jiaotong University and Shaanxi Provincial Cancer Hospital.Results：A total of 87 patients were involved in this study,including 30 cases with gBRCA1/2m and 57 cases with BRCA1/2 wild-type.The average onset ages of two groups were 53 and 54 years old,respectively.There was no statistical difference between two groups in age,histopathology,surgery,FIGO stage,and adjuvant treatment (P>0.05).90.00% of patients in the gBRCA1/2m group experienced hematological toxicities during chemotherapy,which was slightly higher than 87.72% of the BRCA1/2 wild-type group (P=1.000).No difference was found between two groups in the type of hematological toxicity and the grade of bone marrow suppression (P=0.845).Grade Ⅲ or higher bone marrow suppression accounted for 23.33% of patients in gBRCA1/2m group,which was a bit higher than 19.30% of the BRCA1/2 wild-type group,but there was no statistical difference (P=0.659).Results were analogous in hemoglobin (P=0.577),platelet (P=0.064),white blood cell (P=0.211) and neutrophil count (P=0.257) between the two groups before and after chemotherapy.Conclusion：Ovarian cancer patients with germline BRCA1/2 mutation showed similar hematological toxicities compared with BRCA1/2 wild-type patients during initial chemotherapy.

References:

[1]SIEGEL RL,MILLER KD,FUCHS HE,et al.Cancer statistics,2022 ［J］.CA Cancer J Clin,2022,72(1):7-33.
[2]COLOMBO N,SESSA C,DUBOIS A,et al.ESMO-ESGO consensus conference recommendations on ovarian cancer:pathology and molecular biology,early and advanced stages,borderline tumours and recurrent diseasedagger ［J］.Ann Oncol,2019,30(5):672-705.
[3]SALANI R,BACKES FJ,FUNG MF,et al.Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies:Society of Gynecologic Oncologists recommendations ［J］.Am J Obstet Gynecol,2011,204(6):466-478.
[4]BAERT A,DEPUYDT J,VAN MAERKEN T,et al.Increased chromosomal radiosensitivity in asymptomatic carriers of a heterozygous BRCA1 mutation ［J］.Breast Cancer Res,2016,18(1):52.
[5]CALLENS C,VAUR D,SOUBEYRAN I,et al.Concordance between tumor and germline BRCA status in high-grade ovarian carcinoma patients in the phase III PAOLA-1/ENGOT-ov25 trial ［J］.J Natl Cancer Inst,2021,113(7):917-923.
[6]VERGOTE I,GONZALEZ-MARTIN A,RAY-COQUARD I,et al.European experts consensus:BRCA/homologous recombination deficiency testing in first-line ovarian cancer ［J］.Ann Oncol,2022,33(3):276-287.
[7]DE PICCIOTTO N,CACHEUX W,ROTH A,et al.Ovarian cancer:Status of homologous recombination pathway as a predictor of drug response ［J］.Crit Rev Oncol Hematol,2016,101:50-59.
[8]SEDIC M,SKIBINSKI A,BROWN N,et al.Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence ［J］.Nat Commun,2015,6:7505.
[9]FRIEDLAENDER A,VUILLEUMIER A,VIASSOLO V,et al.BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients ［J］.Breast Cancer Res Treat,2019,174(3):775-783.
[10]TOMAO F,MUSACCHIO L,DI MAURO F,et al.Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients［J］.Gynecol Oncol,2019,154(1):138-143.
[11]DROOGER JC,HEEMSKERK-GERRITSEN BAM,SMALLENBROEK N,et al.Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer ［J］.Breast Cancer Res Treat,2016,156(3):557-566.
[12]DUSKA LR,KOHN EC.The new classifications of ovarian,fallopian tube,and primary peritoneal cancer and their clinical implications ［J］.Ann Oncol,2017,28(8):viii8-viii12.
[13]BEREK JS,KEHOE ST,KUMAR L,et al.Cancer of the ovary,fallopian tube,and peritoneum ［J］.Int J Gynaecol Obstet,2018,143(2):59-78.
[14]NCI.Common Terminology Criteria for Adverse Events(CTCAE) version 4.0 ［EB/OL］.U.S.Department of Health and Human Service,2009:3-5(2010-06-14)［2022-05-25］.https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
[15]CHEN P,HUHTINEN K,KAIPIO K,et al.Identification of prognostic groups in high-grade serous ovarian cancer treated with platinum-taxane chemotherapy ［J］.Cancer Res,2015,75(15):2987-2998.
[16]BADORA-RYBICKA A,BUDRYK M,NOWARA E,et al.Treatment related toxicity in BRCA1-associated epithelial ovarian cancer - is DNA repairing impairment associated with more adverse events［J］.Contemp Oncol (Pozn),2016,20(5):381-384.
[17]EGLOFF H,JATOI A.Do ovarian cancer patients with a family history of cancer (suspected BRCA1 or BRCA2 mutation) suffer greater chemotherapy toxicity［J］.Cancer Invest,2016,34(10):531-535.
[18]KOTSOPOULOS J,WILLOWS K,TRAT S,et al.BRCA mutation status is not associated with increased hematologic toxicity among patients undergoing platinum-based chemotherapy for ovarian cancer ［J］.Int J Gynecol Cancer,2018,28(1):69-76.
[19]WEITZNER O,YAGUR Y,KADAN Y,et al.Chemotherapy toxicity in BRCA mutation carriers undergoing first-line platinum-based chemotherapy［J］.Oncologist,2019,24(12):e1471-e1475.
[20]GILLEN J,MILLER A,BELL-MCGUINN KM,et al.Post hoc analyses of GOG 9923:Does BRCA status affect toxicities?:An NRG oncology study［J］.Gynecol Oncol,2021,161(2):512-515.
[21]AGHAJANIAN C,SWISHER EM,OKAMOTO A,et al.Impact of veliparib,paclitaxel dosing regimen,and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial［J］.Gynecol Oncol,2022,164(2):278-287.
[22]WEST AH,KNOLLMAN H,DUGAN J,et al.Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy:A retrospective matched cohort study［J］.Cancer Med,2019,8(12):5609-5618.

Memo

Memo:
陕西省自然科学基础研究计划（编号：S2020-JC-QN-0802）
Last Update: 1900-01-01